# Phase 1/2 Small Cell Lung Carcinoma trials: 46 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 46 trials in phase 1/2 for Small Cell Lung Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Small Cell Lung Carcinoma trials: 46 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/small-cell-lung-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 46
- Recruiting or not yet: 46
- Read on: November 19, 2026

## Trials

The 25 newest of 46, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 7, 2026 | NCT07864207 | Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic) | IDP Discovery Pharma S.L. | Phase 1/2 | Recruiting | Small Cell Lung Cancer ( SCLC ) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864207) |
| September 28, 2026 | NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | Boehringer Ingelheim | Phase 1/2 | Recruiting | Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843940) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 4, 2026 | NCT07744256 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Beijing Biotech | Phase 1/2 | Recruiting | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744256) |
| July 28, 2026 | NCT07730021 | A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1/2 | Recruiting | Locally Advanced or Metastatic Solid Tumors | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730021) |
| July 16, 2026 | NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine... | Boehringer Ingelheim | Phase 1/2 | Recruiting | Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707895) |
| May 4, 2026 | NCT07564401 | A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy | Novartis Pharmaceuticals | Phase 1/2 | Recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564401) |
| April 30, 2026 | NCT07559929 | A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1/2 | Recruiting | Small Cell Lung Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559929) |
| April 2, 2026 | NCT07508852 | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer | Peking University First Hospital | Phase 1/2 | Recruiting | SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07508852) |
| March 23, 2026 | NCT07488676 | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1/2 | Recruiting | Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488676) |
| March 18, 2026 | NCT07480213 | Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Beijing Biotech | Phase 1/2 | Recruiting | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480213) |
| March 16, 2026 | NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | Shanghai JMT-Bio Inc. | Phase 1/2 | Not yet recruiting | Non-Small Cell Lung Cancer, Small Cell Lung Cancer | 596 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472647) |
| February 17, 2026 | NCT07414927 | A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell... | Shanghai Best-Link Bioscience, LLC | Phase 1/2 | Not yet recruiting | Small Cell Carcinoma of Lung | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414927) |
| February 12, 2026 | NCT07407933 | A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407933) |
| January 8, 2026 | NCT07325136 | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small... | Bristol-Myers Squibb | Phase 1/2 | Recruiting | Relapsed/Refractory Small Cell Lung Cancer | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07325136) |
| December 12, 2025 | NCT07278479 | Study of \[212Pb\]Pb-DOTAM-MAM279 (\[212Pb\]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | Molecular Partners AG | Phase 1/2 | Recruiting | Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary... | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07278479) |
| October 6, 2025 | NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07208773) |
| October 3, 2025 | NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1/2 | Not yet recruiting | Small Cell Carcinoma, Small Cell Carcinoma of Lung, Small Cell Lung Cancer ( SCLC ), Small Cell Cervical Carcinoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206563) |
| September 24, 2025 | NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Radiopharm Theranostics, Ltd | Phase 1/2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer... | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189871) |
| September 16, 2025 | NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | IDEAYA Biosciences | Phase 1/2 | Recruiting | Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3 | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07174583) |
| September 4, 2025 | NCT07155200 | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | Washington University School of Medicine | Phase 1/2 | Recruiting | Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07155200) |
| September 3, 2025 | NCT07153055 | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07153055) |
| July 17, 2025 | NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | GV20 Therapeutics | Phase 1/2 | Recruiting | Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS... | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070518) |
| June 26, 2025 | NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors... | Avenzo Therapeutics, Inc. | Phase 1/2 | Recruiting | Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer... | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07038343) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Suzhou Zelgen Biopharmaceuticals Co.,Ltd](https://specstream.ai/data/clinical-trials/company/suzhou-zelgen-biopharmaceuticals-co-ltd) | 3 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 2 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 2 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 2 |
| [MediLink Therapeutics (Suzhou) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/medilink-therapeutics-suzhou-co-ltd) | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| IDP Discovery Pharma S.L. | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| Shanghai Public Health Clinical Center | 1 |
| Arvinas Inc. | 1 |
| Heronova Pharmaceuticals | 1 |
| Shanghai Best-Link Bioscience, LLC | 1 |
| Molecular Partners AG | 1 |
| PMV Pharmaceuticals, Inc | 1 |
| Anhui Provincial Hospital | 1 |
| Neonc Technologies, Inc. | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| [Shanghai JMT-Bio Inc.](https://specstream.ai/data/clinical-trials/company/shanghai-jmt-bio-inc) | 1 |
| IDEAYA Biosciences | 1 |
| Phanes Therapeutics | 1 |
| Hangzhou DAC Biotechnology Co., Ltd. | 1 |
| Peking University First Hospital | 1 |
| VM Oncology, LLC | 1 |
| Sichuan University | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 27 |
| China | 25 |
| Spain | 10 |
| Australia | 8 |
| Japan | 7 |
| France | 7 |
| United Kingdom | 6 |
| Italy | 5 |
| South Korea | 4 |
| Taiwan | 4 |
| Germany | 4 |
| Poland | 4 |
| Singapore | 3 |
| Belgium | 3 |
| Romania | 2 |
| Israel | 2 |
| Turkey (Türkiye) | 2 |
| Netherlands | 2 |
| Canada | 2 |
| Argentina | 1 |
| Chile | 1 |
| Puerto Rico | 1 |
| Hungary | 1 |
| Czechia | 1 |
| Denmark | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Powder coating companies in the United States](https://specstream.ai/data/businesses/powder-coating-companies/united-states)
- [HVAC contractors in the United States](https://specstream.ai/data/businesses/hvac-contractors/united-states)
- [Commercial real estate firms in the United States](https://specstream.ai/data/businesses/commercial-real-estate-firms/united-states)
- [Well drilling companies in the United States](https://specstream.ai/data/businesses/well-drilling-companies/united-states)
- [Polish restaurants in the United States](https://specstream.ai/data/businesses/polish-restaurants/united-states)
- [Hotel bars in the United States](https://specstream.ai/data/businesses/hotel-bars/united-states)
